Addressing the fill–finish bottleneck for next-generation nucleic acid therapeutics

“Addressing fill–finish challenges is not merely operational but strategic.”

The rapid advancement of nucleic acid therapeutics, demonstrated at global scale through mRNA vaccine deployment, has transformed biopharmaceutical development by positioning genetic material as a programmable therapeutic platform. As the field shifts toward a durable role in precision medicine, a key constraint has emerged: the fill–finish process. Fill–finish is no longer a passive downstream step. For nucleic acid drug products, it represents the final and often most vulnerable translation of molecular innovation into a viable medicine. Unless it evolves alongside upstream advances, it risks becoming the primary bottleneck limiting scalability, robustness, and access.

Please enter your email to access content Read now